Fiduciary Alliance LLC Acquires 89,635 Shares of Pfizer Inc. $PFE

Key Points

• Fiduciary Alliance LLC significantly increased its holdings in Pfizer by 935.2% during the second quarter, acquiring an additional 89,635 shares and bringing their total to 99,220 shares valued at approximately $2.4 million.
• Pfizer recently reported quarterly earnings of $0.78 per share, exceeding expectations and reflecting a 10.3% year-over-year revenue increase to $14.65 billion.
• The company declared a quarterly dividend of $0.43, resulting in an annualized dividend of $1.72 and a yield of 7.2%, with a payout ratio of 91.49%.

Fiduciary Alliance LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 935.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 99,220 shares of the biopharmaceutical company's stock after buying an additional 89,635 shares during the period. Fiduciary Alliance LLC's holdings in Pfizer were worth $2,405,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter valued at $27,000. North Capital Inc. bought a new stake in Pfizer during the first quarter valued at $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer during the fourth quarter worth about $30,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Pfizer stock opened at $23.88 on Wednesday. The stock's 50 day simple moving average is $24.73 and its two-hundred day simple moving average is $24.25. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market cap of $135.77 billion, a price-to-earnings ratio of 12.70, a PEG ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PFE. Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Morgan Stanley lifted their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Finally, Berenberg Bank decreased their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Pfizer has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.